Saxagliptin
Onglyza
- Dosage form
- Tablet
- Available strengths
- 2.5 mg, 5 mg
- Drug class
- Dipeptidyl peptidase-4 (DPP-4) inhibitor (oral antihyperglycemic agent)
- Common brand
- Onglyza
Clinical overview. Saxagliptin (Onglyza) is a DPP-4 inhibitor taken once daily to improve blood sugar control in adults with type 2 diabetes, usually alongside metformin, a sulfonylurea, or insulin. It works by boosting the body's own incretin hormones to increase insulin release and lower glucagon after meals. Saxagliptin can be taken with or without food, but carries warnings for heart failure, pancreatitis, and severe joint pain.
Indication
Common therapeutic uses
- Saxagliptin is used to improve blood sugar control in adults with type 2 diabetes mellitus, in combination with metformin, a sulfonylurea, both metformin and a sulfonylurea, or insulin.
- Saxagliptin is intended for use when diet, exercise, and existing therapy do not provide adequate blood sugar control on their own.
- Saxagliptin is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.
Pregnancy
Risk assessment and monitoring considerations
- Saxagliptin is not recommended during pregnancy, as there are no adequate studies in pregnant women and animal studies are not always predictive of effects in humans.
Breastfeeding
Infant exposure considerations
- Saxagliptin should not be used while breastfeeding, since it passes into the milk of lactating animals and it is not known whether it passes into human breast milk.
Geriatrics
Dosing and tolerability considerations
- No dosage adjustment is required for saxagliptin based on age alone, but older adults are more likely to have reduced kidney function, so kidney function should be checked before starting and periodically during treatment.
Pediatrics
Use in children and adolescents
- Saxagliptin has not been authorized for use in patients under 18 years of age, as its safety and effectiveness have not been established in this population.
Dosage & Administration
Practical dosing and administration
- The recommended dose of saxagliptin is 5 mg taken once daily by mouth for all approved uses.
- Kidney function should be assessed before starting saxagliptin and periodically thereafter.
- In patients with moderate kidney impairment (eGFR under 45 mL/min/1.73 m²) or severe kidney impairment (eGFR under 30 mL/min/1.73 m²), the dose should be reduced to 2.5 mg once daily.
- Saxagliptin is not recommended for patients with end-stage kidney disease requiring hemodialysis.
- No dose adjustment is needed for mild liver impairment, but saxagliptin is not recommended for patients with moderate or severe liver impairment due to limited clinical experience.
- Tablets should be swallowed whole and must not be split or crushed.
- If a dose is missed, it should be taken as soon as remembered, but a double dose should never be taken on the same day.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is limited specific information on saxagliptin overdose in humans; management should be supportive and guided by the patient's clinical condition.
- Saxagliptin and its major active metabolite can be removed from the blood by hemodialysis, which may be considered in a significant overdose.
Common side effects
Frequently reported tolerability concerns
- Upper respiratory tract infection (nasopharyngitis) may occur.
- Bronchitis may occur.
- Urinary tract infection may occur.
- Headache may occur.
- Low blood sugar (hypoglycemia) may occur, particularly when saxagliptin is combined with a sulfonylurea or insulin.
- Joint pain (arthralgia) may occur.
- Back pain may occur.
- Swelling of the hands, feet, or legs (peripheral edema) may occur.
- Diarrhea or stomach upset may occur.
- Sinusitis may occur.
- Nausea or vomiting may occur.
- Heartburn (gastroesophageal reflux) may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Saxagliptin has been linked to a higher rate of hospitalization for heart failure, particularly in patients who already have a history of heart failure or kidney impairment.
- Acute and chronic pancreatitis, sometimes severe, has been reported with saxagliptin use.
- Severe and disabling joint pain has been reported, which may begin anywhere from one day to years after starting treatment and usually resolves after stopping the drug.
- Serious allergic reactions, including anaphylaxis and angioedema (swelling of the face, lips, tongue, or throat), have been reported, sometimes after the very first dose.
- Severe exfoliative skin reactions, including Stevens-Johnson syndrome, have been reported.
- Bullous pemphigoid, a blistering skin condition that may require hospitalization, has been reported.
- A dose-related decrease in lymphocyte (white blood cell) count has been observed.
- Seek urgent medical attention for shortness of breath, swelling of the legs or abdomen, severe abdominal pain, facial or throat swelling, difficulty breathing, or widespread blistering or peeling of the skin.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with a history of congestive heart failure, especially those who also have kidney impairment or a prior heart attack, and watch for new or worsening heart failure symptoms.
- Use with caution in patients with a history of pancreatitis, gallstones, alcoholism, or high triglycerides.
- Use with caution in patients also taking a sulfonylurea or insulin, since the dose of those medications may need to be lowered to reduce the risk of low blood sugar.
- Use with caution in patients with reduced kidney function, with dose adjustment as needed.
- Use with caution in immunocompromised patients, since the effect of saxagliptin on lymphocyte counts in this group is unknown.
- Use with caution when driving or operating machinery if fatigue or dizziness occurs.
- Use with caution and monitor for new skin changes as part of routine diabetes care.
- Patients under physical stress such as fever, trauma, infection, or surgery may temporarily lose blood sugar control and may need to switch to insulin.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with a history of hypersensitivity, including anaphylaxis or angioedema, to saxagliptin or to another DPP-4 inhibitor.
- Contraindicated in patients with diabetic ketoacidosis or diabetic coma/precoma.
- Contraindicated in patients with type 1 diabetes mellitus.
Drug interactions
Clinically relevant combinations
- Strong inducers of the CYP3A4/5 enzyme, such as carbamazepine, dexamethasone, phenobarbital, phenytoin, and rifampin, may lower saxagliptin blood levels and reduce its blood-sugar-lowering effect.
- Combining saxagliptin with a sulfonylurea, such as glyburide, or with insulin increases the risk of hypoglycemia, and a lower dose of the sulfonylurea or insulin may be needed.
- No clinically meaningful interaction was found between saxagliptin and metformin, glyburide, pioglitazone, digoxin, simvastatin, diltiazem, ketoconazole, omeprazole, or a combined antacid product.
- Saxagliptin did not meaningfully change the levels of metformin, glyburide, pioglitazone, digoxin, simvastatin, diltiazem, ketoconazole, or an estrogen/progestin oral contraceptive.
- Saxagliptin does not significantly inhibit or induce most major drug-metabolizing enzymes or P-glycoprotein, so it is unlikely to alter the clearance of most other medications.
Food interactions
Meal-related administration
- Saxagliptin can be taken with or without food; there are no known clinically significant food interactions, though grapefruit juice may modestly increase saxagliptin blood levels.
Time of administration
Practical scheduling
- Saxagliptin is taken once daily, at any convenient time of day, with or without food.
Storage
Product handling
- Store saxagliptin tablets at room temperature (15 to 30°C).
Patient take-away
Key counselling points for a quick closing summary
- Saxagliptin helps control blood sugar but does not replace a healthy diet, regular exercise, and routine blood sugar monitoring.
- Tell your doctor right away about persistent severe stomach pain, new joint pain, unusual swelling or shortness of breath, or any skin blistering while taking saxagliptin.
- If you also take a sulfonylurea or insulin, know the signs of low blood sugar, such as shakiness, sweating, or confusion, and how to treat it, since combining these medicines raises that risk.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.